These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9748138

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.
    Eur Urol; 2007 May 23; 51(5):1259-66. PubMed ID: 16806661
    [Abstract] [Full Text] [Related]

  • 7. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M.
    J Urol; 2000 Nov 23; 164(5):1819-24. PubMed ID: 11025776
    [Abstract] [Full Text] [Related]

  • 8. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z, Wenlv S.
    Jpn J Clin Oncol; 2004 Jul 23; 34(7):414-9. PubMed ID: 15342669
    [Abstract] [Full Text] [Related]

  • 9. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H, Nonomura N, Nishimura K, Oka D, Shiba M, Nakai Y, Nakayama M, Tsujimura A, Aozasa K, Okuyama A.
    BJU Int; 2009 Feb 23; 103(4):470-4. PubMed ID: 18778349
    [Abstract] [Full Text] [Related]

  • 10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 23; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 11. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET.
    Prostate; 2006 Feb 15; 66(3):248-56. PubMed ID: 16175585
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec 15; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T, Hara N, Kitamura Y, Komatsubara S.
    Urology; 2007 Oct 15; 70(4):702-5. PubMed ID: 17991541
    [Abstract] [Full Text] [Related]

  • 15. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L, Purrazzella R, Brustein S, Fearn P, Leibel SA, Kattan MW.
    Cancer; 2002 Oct 01; 95(7):1451-6. PubMed ID: 12237913
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, Fasolis G.
    Eur Urol; 2005 Aug 01; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH.
    J Urol; 2003 Apr 01; 169(4):1320-4. PubMed ID: 12629352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.